Ποια είναι η τιμή για GenSight Biologics S.A. (SIGHT)

Η τιμή για GenSight Biologics S.A. (SIGHT) είναι $0.12098783

Ποια είναι η κεφαλαιοποίηση αγοράς για GenSight Biologics S.A. (SIGHT)

Η κεφαλαιοποίηση αγοράς για GenSight Biologics S.A. (SIGHT) είναι $19.72M

GenSight Biologics S.A. (SIGHT) Τιμή και Κεφαλαιοποίηση Αγοράς

GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.

Η τιμή για SIGHT	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$32,555.70 $19.72M	NVDA	$5.307T	+26,908,142.59%
$27,918.59 $19.72M	AAPL	$4.551T	+23,075,437.31%
$25,486.88 $19.72M	GOOG	$4.154T	+21,065,559.84%
$22,015.62 $19.72M	MSFT	$3.589T	+18,196,455.21%
$17,158.56 $19.72M	AMZN	$2.797T	+14,181,958.43%

Η τιμή για SIGHT

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$32,555.70 $19.72M